These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 26430247)

  • 1. The UK Risk-Sharing Scheme for interferon-beta and glatiramer acetate in multiple sclerosis. Outcome of the year-6 analysis.
    Duddy M; Palace J
    Pract Neurol; 2016 Feb; 16(1):4-6. PubMed ID: 26430247
    [No Abstract]   [Full Text] [Related]  

  • 2. Multiple sclerosis disease-modifying therapy and pregnancy.
    Miller AE
    Mult Scler; 2016 May; 22(6):715-6. PubMed ID: 27207870
    [No Abstract]   [Full Text] [Related]  

  • 3. Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis.
    Iaffaldano P; Lucisano G; Pozzilli C; Brescia Morra V; Ghezzi A; Millefiorini E; Patti F; Lugaresi A; Zimatore GB; Marrosu MG; Amato MP; Bertolotto A; Bergamaschi R; Granella F; Coniglio G; Tedeschi G; Sola P; Lus G; Ferrò MT; Iuliano G; Corea F; Protti A; Cavalla P; Guareschi A; Rodegher M; Paolicelli D; Tortorella C; Lepore V; Prosperini L; Saccà F; Baroncini D; Comi G; Trojano M;
    Brain; 2015 Nov; 138(Pt 11):3275-86. PubMed ID: 26362907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of immunomodulatory therapy with interferon-β or glatiramer acetate on multiple sclerosis-associated uveitis.
    Velazquez-Villoria D; Macia-Badia C; Segura-García A; Pastor Idoate S; Arcos-Algaba G; Velez-Escola L; García-Arumí J
    Arch Soc Esp Oftalmol; 2017 Jun; 92(6):273-279. PubMed ID: 28188020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disease modifying therapies in multiple sclerosis: could a baseline thyroid check-up drive the therapeutic choice between interferon-β and glatiramer acetate?
    Rotondi M; Bergamaschi R; Chiovato L
    Mult Scler; 2014 Dec; 20(14):1918-9. PubMed ID: 24812044
    [No Abstract]   [Full Text] [Related]  

  • 6. Multiple Sclerosis.
    Reich DS; Lucchinetti CF; Calabresi PA
    N Engl J Med; 2018 Jan; 378(2):169-180. PubMed ID: 29320652
    [No Abstract]   [Full Text] [Related]  

  • 7. Long-term follow-up for multiple sclerosis patients initially treated with interferon-beta and glatiramer acetate.
    Healy BC; Glanz BI; Zurawski JD; Mazzola M; Chitnis T; Weiner HL
    J Neurol Sci; 2018 Nov; 394():127-131. PubMed ID: 30248571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple sclerosis: monotherapy rules.
    Hauser SL; Josephson SA; Johnston SC
    Ann Neurol; 2013 Mar; 73(3):A5-6. PubMed ID: 23596013
    [No Abstract]   [Full Text] [Related]  

  • 9. Editorial: the pitfalls of combination therapy.
    Vermersch P
    Int MS J; 2006 Nov; 13(3):75-6. PubMed ID: 17101074
    [No Abstract]   [Full Text] [Related]  

  • 10. Interferon beta and glatiramer acetate therapy.
    McGraw CA; Lublin FD
    Neurotherapeutics; 2013 Jan; 10(1):2-18. PubMed ID: 23264098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Logistics and description of treatment technology (the protocol for using disease modifying drugs--DMD)].
    Federal service on surveillance in healthcare and social development (Roszdravnadzor)
    Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(2 Pt 2):93-8. PubMed ID: 21916163
    [No Abstract]   [Full Text] [Related]  

  • 12. [The technology of treatment of multiple sclerosis with long-term immunomodulating drugs (disease modifying drugs--DMD)--beta-interferons and glatiramer-acetate].
    Federal service on surveillance in healthcare and social development (Roszdravnadzor)
    Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(2 Pt 2):86-92. PubMed ID: 21916162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing the long-term effectiveness of interferon-beta and glatiramer acetate in multiple sclerosis: final 10-year results from the UK multiple sclerosis risk-sharing scheme.
    Palace J; Duddy M; Lawton M; Bregenzer T; Zhu F; Boggild M; Piske B; Robertson NP; Oger J; Tremlett H; Tilling K; Ben-Shlomo Y; Lilford R; Dobson C
    J Neurol Neurosurg Psychiatry; 2019 Mar; 90(3):251-260. PubMed ID: 30242090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis.
    Kalincik T; Jokubaitis V; Izquierdo G; Duquette P; Girard M; Grammond P; Lugaresi A; Oreja-Guevara C; Bergamaschi R; Hupperts R; Grand'Maison F; Pucci E; Van Pesch V; Boz C; Iuliano G; Fernandez-Bolanos R; Flechter S; Spitaleri D; Cristiano E; Verheul F; Lechner-Scott J; Amato MP; Cabrera-Gomez JA; Saladino ML; Slee M; Moore F; Gray O; Paine M; Barnett M; Havrdova E; Horakova D; Spelman T; Trojano M; Butzkueven H;
    Mult Scler; 2015 Aug; 21(9):1159-71. PubMed ID: 25480857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Consensus statement of the Canadian MS CLinics Network on: the use of disease modifying agents in multiple sclerosis.
    Oger J; Freedman M
    Can J Neurol Sci; 1999 Nov; 26(4):274-5. PubMed ID: 10610197
    [No Abstract]   [Full Text] [Related]  

  • 16. Fatigue Improvement after Switching Multiple Sclerosis Treatment from Interferon-β to Glatiramer Acetate in Clinical Practice.
    Meca-Lallana J; Hernández L; Caminero AB; Girón JM; Cano-Orgaz A; Carcelén-Gadea M; Muñoz D; Durán-Ferreras E; Martín-Hernández J; Sánchez-de la Rosa R;
    Eur Neurol; 2016; 76(1-2):40-7. PubMed ID: 27376845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Hepatitis induced by glatiramer acetate].
    Fernández Fernández N; Joao Matias D; Pisabarros Blanco C; Rodríguez Martín L; Aparicio Cabezudo M; Linares Torres P; Hernando Martín M; Olcoz Goñi JL
    Gastroenterol Hepatol; 2015 Apr; 38(4):280-1. PubMed ID: 25042243
    [No Abstract]   [Full Text] [Related]  

  • 18. The Multiple Sclerosis Risk Sharing Scheme Monitoring Study--early results and lessons for the future.
    Pickin M; Cooper CL; Chater T; O'Hagan A; Abrams KR; Cooper NJ; Boggild M; Palace J; Ebers G; Chilcott JB; Tappenden P; Nicholl J
    BMC Neurol; 2009 Jan; 9():1. PubMed ID: 19126193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenomics of interferon beta and glatiramer acetate response: a review of the literature.
    Mahurkar S; Suppiah V; O'Doherty C
    Autoimmun Rev; 2014 Feb; 13(2):178-86. PubMed ID: 24189284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of interferon Beta and glatiramer acetate in multiple sclerosis.
    Goodin DS
    Semin Neurol; 2013 Feb; 33(1):13-25. PubMed ID: 23709209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.